What are the key takeaways from this BioCentury This Week episode?

Key insights include: **Biotech follow-on strength vs. venture lag:** Over $7B was raised in follow-on financings in Q1 2026—nearly matching all of 2025—with deals like Xenon upsizing from $500M to $750M on strong data. However, venture financing sits at roughly $5.4B for the quarter, potentially the lowest since 2017, suggesting a lag between public and private market recovery cycles.; **KV7 channel revival strategy:** Xenon's azetukalner achieved a 42% reduction in median monthly seizure frequency versus placebo with an extraordinarily low p-value in phase three focal epilepsy. The molecule avoids predecessor GSK drug safety issues—skin discoloration and retinal abnormalities—by preventing dimerization via a novel chemical structure, with NDA submission planned for Q3 2025.; **Dosing timing as a side effect mitigation tool:** KV7 openers cause dizziness and somnolence by allowing potassium ions to flow out of neurons, stabilizing membrane potential. Xenon addresses this by extending the molecule's half-life for once-daily dosing administered in the evening, so peak side effects occur during sleep rather than waking hours—a replicable strategy for CNS drugs with sedating mechanisms.

What did Steven Hansen and Selena Koch discuss on BioCentury This Week?

BioCentury This Week examines biotech capital markets momentum amid geopolitical uncertainty, Xenon Pharmaceuticals' phase three epilepsy data validating the KV7 potassium channel target, and the shifting Friedreich's ataxia pipeline from mitochondrial stabilizers toward frataxin-restoring gene therapies, with at least five programs now in development. Key topics include: **Biotech follow-on strength vs. venture lag:** Over $7B was raised in follow-on financings in Q1 2026—nearly matching all of 2025—with deals like Xenon upsizing from $500M to $750M on strong data. However, venture financing sits at roughly $5.4B for the quarter, potentially the lowest since 2017, suggesting a lag between public and private market recovery cycles.; **KV7 channel revival strategy:** Xenon's azetukalner achieved a 42% reduction in median monthly seizure frequency versus placebo with an extraordinarily low p-value in phase three focal epilepsy. The molecule avoids predecessor GSK drug safety issues—skin discoloration and retinal abnormalities—by preventing dimerization via a novel chemical structure, with NDA submission planned for Q3 2025..

How long is this episode of BioCentury This Week?

This episode is 24 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

BioCentury This Week

Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline

March 17, 2026

24 min episode · 2 min read

Steven Hansen,Selena Koch,Danielle Golovin

Episode

24 min

Read time

2 min

Topics

Health & Wellness, Fundraising & VC, Leadership

AI-Generated Summary

Published Mar 18, 2026

Key Takeaways

✓Biotech follow-on strength vs. venture lag: Over $7B was raised in follow-on financings in Q1 2026—nearly matching all of 2025—with deals like Xenon upsizing from $500M to $750M on strong data. However, venture financing sits at roughly $5.4B for the quarter, potentially the lowest since 2017, suggesting a lag between public and private market recovery cycles.
✓KV7 channel revival strategy: Xenon's azetukalner achieved a 42% reduction in median monthly seizure frequency versus placebo with an extraordinarily low p-value in phase three focal epilepsy. The molecule avoids predecessor GSK drug safety issues—skin discoloration and retinal abnormalities—by preventing dimerization via a novel chemical structure, with NDA submission planned for Q3 2025.
✓Dosing timing as a side effect mitigation tool: KV7 openers cause dizziness and somnolence by allowing potassium ions to flow out of neurons, stabilizing membrane potential. Xenon addresses this by extending the molecule's half-life for once-daily dosing administered in the evening, so peak side effects occur during sleep rather than waking hours—a replicable strategy for CNS drugs with sedating mechanisms.
✓Friedreich's ataxia gene therapy differentiation: Among five FA gene therapy programs, four use AAV vectors while Replay Holdings' spinout Calib uses herpes simplex virus vectors, which offer higher payload capacity. This allows delivery of the full frataxin gene with its native regulatory elements—exceeding AAV's five-kilobase limit—potentially producing more physiologically accurate protein expression across affected tissues.
✓FA accelerated approval pathway established: Alexio Therapeutics' LX2006 secured FDA agreement on an accelerated approval pathway targeting FA-associated cardiomyopathy, the leading cause of death in FA patients. The agreed endpoints are left ventricular mass index and frataxin expression levels—providing a regulatory template other FA gene therapy developers can reference when designing their own pivotal trial endpoints.

What It Covers

BioCentury This Week examines biotech capital markets momentum amid geopolitical uncertainty, Xenon Pharmaceuticals' phase three epilepsy data validating the KV7 potassium channel target, and the shifting Friedreich's ataxia pipeline from mitochondrial stabilizers toward frataxin-restoring gene therapies, with at least five programs now in development.

Key Questions Answered

•Biotech follow-on strength vs. venture lag: Over $7B was raised in follow-on financings in Q1 2026—nearly matching all of 2025—with deals like Xenon upsizing from $500M to $750M on strong data. However, venture financing sits at roughly $5.4B for the quarter, potentially the lowest since 2017, suggesting a lag between public and private market recovery cycles.
•KV7 channel revival strategy: Xenon's azetukalner achieved a 42% reduction in median monthly seizure frequency versus placebo with an extraordinarily low p-value in phase three focal epilepsy. The molecule avoids predecessor GSK drug safety issues—skin discoloration and retinal abnormalities—by preventing dimerization via a novel chemical structure, with NDA submission planned for Q3 2025.
•Dosing timing as a side effect mitigation tool: KV7 openers cause dizziness and somnolence by allowing potassium ions to flow out of neurons, stabilizing membrane potential. Xenon addresses this by extending the molecule's half-life for once-daily dosing administered in the evening, so peak side effects occur during sleep rather than waking hours—a replicable strategy for CNS drugs with sedating mechanisms.
•Friedreich's ataxia gene therapy differentiation: Among five FA gene therapy programs, four use AAV vectors while Replay Holdings' spinout Calib uses herpes simplex virus vectors, which offer higher payload capacity. This allows delivery of the full frataxin gene with its native regulatory elements—exceeding AAV's five-kilobase limit—potentially producing more physiologically accurate protein expression across affected tissues.
•FA accelerated approval pathway established: Alexio Therapeutics' LX2006 secured FDA agreement on an accelerated approval pathway targeting FA-associated cardiomyopathy, the leading cause of death in FA patients. The agreed endpoints are left ventricular mass index and frataxin expression levels—providing a regulatory template other FA gene therapy developers can reference when designing their own pivotal trial endpoints.

Notable Moment

Biotech venture financing in Q1 2026 may reach its lowest quarterly total in roughly nine years, despite public market follow-ons performing strongly. The divergence suggests rising valuations are making venture investors more selective, even as generalist capital returns to larger public biotech deals.

Know someone who'd find this useful?

Episode Transcript

Biotech follow on financings have been getting out with some upsizing on the back of good data, and we're also seeing IPOs get out on Nasdaq. But will geopolitics scuttle this new momentum? We'll discuss the capital markets for biotech on this week's BioCentury This Week podcast. Plus, late stage epilepsy data from xenon are reviving the biotech stock and the k v seven target. And in our rare disease spotlight, we'll take a look at what's in the pipeline for Friedreich's ataxia. I'm Jeff Cranmer, host of the BioCentury This Week podcast. And joining me today are my colleagues. Steven Hansen, director of biopharma intelligence. Selena Koch, executive editor. And Danielle Golovin, senior biopharma analyst. Well, we've just wrapped our fifth East West Biopharma Summit in Seoul. I am back in the Bay Area and deeply jet lagged, but very impressed with what is happening in Seoul and in Daejeon around biotech. Good energy. It's really starting to buzz. We had investors and companies from all over Asia, from Europe, from Canada, from The US checking out what is happening in Seoul. And there really does seem to be good energy there. So look for more out of Korea. You could check out our recent coverage. We took a look at some neurology companies that are starting to make their mark raising significant venture capital. And we're also starting to see some Korean biotech setup shop in Japan at the IPARK Center. That's a former Takeda site. You can check out more on the special edition of the podcast that we recorded live on stage at the event. It was the final event of the conference, and we put that out on Friday. So you can get thoughts from two of the attendees from the conference, as well as Josh and Simone, and it's well worth checking out. And now BioCentury's energy turns to Bioequity Europe. Right, Steven? That'll be in Prague. You'll be, taking the podcast on the road in Prague. Yeah? That's right. Well, I I wanted to ask you, Jeff. So what was your favorite food that you had while you were in Seoul? Galbi. I probably had galbi twice a day. What is So it's I'm I'm sorry. I'm a little naive. What is what is galbi? Yeah. Galbi. It's grilled ribs and they they sort of Oh. Set up a nice, like, either hot coals right on the table in front of you or, you know, some other contraption and, they cook it right there for you. Goes down very well with, insert delicious Korean beer of your choice. Korean beer is very, very light, which is is somewhat dangerous. And a little bit of soju and, of course, kimchi with every meal. That was, definitely, definitely the way to go. But, yeah, I snuck out many times and and and got some good Galbi. Alright, Steven. There's a war going on. And, I am curious. You you know, you've been watching the markets. …

Get the full transcript (4,096 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all BioCentury This Week transcripts →